SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
大闸蟹和皮皮虾
Lv3
270 积分
2023-02-09 加入
最近求助
最近应助
互助留言
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
1个月前
已关闭
Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study
1个月前
已关闭
OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
1个月前
已关闭
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
1个月前
已完结
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
1个月前
已完结
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
1个月前
已完结
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
2个月前
已完结
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer
2个月前
已完结
Discovery of a First-in-Class GPR183 Antagonist for the Potential Treatment of Rheumatoid Arthritis
2个月前
已完结
BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus
3个月前
已完结
没有进行任何应助
没有应助【积分已退回】
1个月前
不需要了e【积分已退回】
1个月前
感谢,点赞,速度真快
2个月前
感谢,点赞
3个月前
感谢,点赞,速度真快
3个月前
感谢,点赞,速度真快
3个月前
感谢,点赞,速度真快
4个月前
感谢,点赞
4个月前
感谢,点赞,速度真快
5个月前
感谢,点赞,速度真快
5个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论